MedTrace Logo

Exogenous Ketone Esters for Drug Resistant Epilepsy

NCT05670847 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-11-27

No results posted yet for this study

Summary

This study aims to investigate the efficacy of add-on exogenous ketone esters for treating children with drug-resistant epilepsy

Conditions

  • Drug Resistant Epilepsy

Interventions

DRUG

Exogenous ketone ester

500 mg/kg orally three times daily (with at least 4 hours between each dose) for 28 days

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Abdelrahim A Sadek, MD, PhD · Sohag University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-10
Primary Completion
2025-06-30
Completion
2025-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05670847 on ClinicalTrials.gov